Key Quantitative Figures - Standalone (Q2 FY27)

  • Revenue from Operations: ₹6,305 million
  • Other Income: ₹907 million
  • Total Income: ₹7,212 million
  • Profit Before Tax (PBT): ₹1,198 million
  • Tax Expense: ₹281 million (Current: ₹253 million, Deferred: ₹28 million)
  • Profit for the Period (Net Profit): ₹917 million
  • Earnings Per Share (Basic & Diluted): ₹0.56
  • Paid-up Equity Share Capital: ₹8,148 million (Face value ₹5 each)

Key Quantitative Figures - Standalone (H1 FY27)

  • Revenue from Operations: ₹12,550 million
  • Other Income: ₹1,555 million
  • Total Income: ₹14,105 million
  • Profit Before Tax (PBT): ₹1,897 million
  • Tax Expense: ₹458 million (Current: ₹420 million, Deferred: ₹38 million)
  • Profit for the Period (Net Profit): ₹1,439 million
  • Earnings Per Share (Basic & Diluted): ₹0.88

Key Quantitative Figures - Consolidated (Q2 FY27)

  • Revenue from Operations: ₹43,889 million
  • Sale of Products: ₹35,312 million
  • Sale of Services: ₹8,138 million
  • Other Operating Revenue: ₹439 million
  • Other Income: ₹345 million
  • Total Income: ₹44,234 million
  • Profit Before Tax (PBT): ₹548 million
  • Tax Expense: ₹(19) million (Current: ₹308 million, Deferred: ₹(327) million)
  • Profit for the Period (Net Profit): ₹567 million
  • Earnings Per Share (Basic & Diluted): ₹0.25

Key Quantitative Figures - Consolidated (H1 FY27)

  • Revenue from Operations: ₹87,249 million
  • Other Income: ₹890 million
  • Total Income: ₹88,139 million
  • Profit Before Tax (PBT): ₹1,824 million
  • Tax Expense: ₹(111) million (Current: ₹1,466 million, Deferred: ₹(1,577) million)
  • Profit for the Period (Net Profit): ₹1,935 million
  • Earnings Per Share (Basic & Diluted): ₹1.12

Management Changes

  • Resignation: Dr. Mandar Shrikant Ghatnekar as Chief Technology Officer, effective close of business hours on December 31, 2026.
  • Appointment: Mr. Mukesh Rathi as Chief Technology Officer, effective January 01, 2027, based on recommendation of Nomination and Remuneration Committee.

Board Meeting Details

  • Commencement: 11:20 A.M.
  • Conclusion: 01:10 P.M.

Segment Performance (Consolidated Q2 FY27)

  • Biosimilars: Revenue ₹28,086 million | PBT ₹325 million
  • Generics: Revenue ₹7,744 million | PBT ₹(304) million
  • Services: Revenue ₹8,327 million | PBT ₹537 million

Exceptional Items

  • Q2 FY27 consolidated exceptional items (net): ₹(67) million (primarily termination benefits)
  • H1 FY27 consolidated exceptional items (net): ₹(202) million

Dividend Information

  • Final dividend of ₹0.50 per equity share (face value ₹5 each) recommended on May 07, 2026, approved in AGM on August 06, 2026, and distributed during the period.

Subsidiaries Included in Consolidation

Financial results include 45 subsidiaries, joint venture (NeoBiocon FZ-LLC), and associate (Iatrica Inc.). Key subsidiaries include Syngene International Limited, Biocon Biologics Limited, and Biocon Pharma Limited.

Auditor Review

  • Limited review conducted by S.R. Batliboi & Associates LLP
  • Review reports are unqualified for both standalone and consolidated financial results

Additional Information

  • The unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind-AS)